Trial Profile

Phase II trial of intranasal doxepin in patients with chronic migraines

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxepin (Primary)
Indications Migraine
Focus Therapeutic Use
Sponsors Winston Pharmaceuticals

Most Recent Events

29 Nov 2010 New trial record
23 Nov 2010 Results were presented at the Lazard Capital Markets 7th Annual Healthcare Conference, according to a Wintson Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com